Filing Analysis
USANA Health Sciences, Inc. has filed an 8-K to announce the release of its second quarter financial results for the period ended July 4, 2026. The filing includes a press release and management commentary regarding the company's financial condition.
📋 Key Facts
- Announced Q2 financial results for the period ending July 4, 2026.
- Management will host a conference call to discuss results via web broadcast and telephone.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Management Commentary).
USANA Health Sciences, Inc. filed an 8-K to announce the release of its third quarter financial results for the period ended September 27, 2025. The filing includes a press release and management commentary regarding the company's financial condition.
📋 Key Facts
- Reporting date: October 22, 2025
- Period covered: Third quarter ended September 27, 2025
- The filing includes a press release (Exhibit 99.1) and Management Commentary (Exhibit 99.2)
- Management will hold a conference call to discuss results via web broadcast and telephone.
USANA Health Sciences, Inc. has issued a press release announcing its preliminary financial results for the third quarter ended September 27, 2025.
📋 Key Facts
- The company announced preliminary Q3 2025 financial results on October 9, 2025.
- The reporting period for these results is the quarter ending September 27, 2025.
- Information was furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
USANA Health Sciences, Inc. has issued an 8-K to announce its financial results for the second quarter ended June 28, 2025. The filing includes a press release and management commentary regarding the company's operational performance.
📋 Key Facts
- Reporting period: Second Quarter ended June 28, 2025.
- Filing date: July 22, 2025.
- The company issued a press release (Exhibit 99.1) and Management Commentary (Exhibit 99.2).
- Management will hold a conference call to discuss results via web broadcast and telephone.
USANA Health Sciences entered into a Third Amended and Restated Credit Agreement with Bank of America on June 27, 2025. The agreement establishes a revolving credit facility with an initial limit of $75 million and an option to increase it up to $200 million.
🚩 Red Flags
- New financial covenants introduced (EBITDA floor and Debt/EBITDA leverage ratio) which could trigger default if performance fluctuates.
📋 Key Facts
- Entered into Third Amended and Restated Credit Agreement on June 27, 2025.
- Revolving credit limit: $75 million (with option to increase to $200 million).
- Lender/Administrative Agent: Bank of America, N.A.
- Financial Covenant 1: Consolidated EBITDA must be ≥ $80M for the four quarters ending June 28, 2025, through July 4, 2026; increasing to ≥ $100M thereafter.
- Financial Covenant 2: Consolidated funded debt to consolidated EBITDA ratio ≤ 2.0 to 1.0.
- No restrictions on cash dividends or share repurchases were included in the agreement.
USANA Health Sciences reported the results of its Annual Meeting of Shareholders held on May 19, 2025. Key outcomes included the election of eight directors and the approval of a new 2025 Equity Incentive Plan.
🚩 Red Flags
- None identified. The filing contains routine annual meeting results.
📋 Key Facts
- Shareholders approved the USANA Health Sciences, Inc. 2025 Equity Incentive Plan, which reserves 2.5 million shares of common stock for issuance.
- The 2015 Equity Incentive Award Plan will no longer be used for new awards following this approval.
- Eight individuals were elected to the Board of Directors: Kevin G. Guest, Xia Ding, John T. Fleming, Gilbert A. Fuller, J. Scott Nixon, Peggie J. Pelosi, Frederic Winssinger, and Timothy E. Wood.
- Shareholders ratified the selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2025.
- The Annual Meeting saw approximately 92% of issued and outstanding shares represented by proxy or in person (17,387,949 shares).
- Executive compensation was approved on an advisory basis.
USANA Health Sciences, Inc. filed an 8-K to announce the release of its first quarter financial results for the period ended March 29, 2025. The filing includes a press release and management commentary regarding the company's financial condition.
📋 Key Facts
- Announced financial results for Q1 ended March 29, 2025.
- Management to hold a conference call with investors via web/telephone.
- Includes 'Management Commentary' as an exhibit (99.2).
- Information is furnished under Item 2.02 and not considered 'filed' for Section 18 liability purposes.
USANA Health Sciences, Inc. filed an amendment to its original December 23, 2024, 8-K to provide required audited financial statements and pro forma information regarding its acquisition of a controlling interest in Hiya Health Products, LLC.
🚩 Red Flags
- None identified; this is a standard regulatory amendment to provide previously omitted required financial data for an acquisition.
📋 Key Facts
- Acquisition of a controlling interest in Hiya Health Products, LLC via a merger agreement dated December 23, 2024.
- The filing includes audited consolidated financial statements for Hiya as of and for the nine months ended September 30, 2024.
- Auditor for the acquired business is WithumSmith+Brown, PC.
- Includes unaudited pro forma condensed combined financial information as of September 30, 2024, and December 31, 2023.
USANA Health Sciences, Inc. issued an 8-K to announce the release of its financial results for the fourth quarter and fiscal year ended December 28, 2024. The filing includes a press release and management commentary regarding the company's operational performance.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 28, 2024.
- Announcement date: February 25, 2025.
- The filing includes a press release (Exhibit 99.1) and Management Commentary (Exhibit 99.2).
- Management scheduled an investor conference call to discuss results.
USANA Health Sciences, Inc. has entered into a definitive agreement to acquire a controlling interest (78.85%) in Hiya Health Products, LLC, a direct-to-consumer online retail business specializing in children's vitamins and supplements.
🚩 Red Flags
- Significant use of debt: The $205 million acquisition relies heavily on existing credit facilities and cash reserves.
- Contingent liabilities: The 'Put Right' starting in 2028 creates a potential future cash outflow obligation based on EBITDA multiples.
📋 Key Facts
- Acquisition of 78.85% membership interest in Hiya Health Products, LLC via a merger with Karate Merger Sub, LLC.
- Total consideration for the 78.85% stake is $205 million.
- Funding sources: $200 million from cash on hand and the balance from borrowings under existing credit facility.
- The remaining 21.15% interest (Class B Units) will be held by Qualified Holders in exchange for cash consideration.
- The transaction includes 'Put Rights' allowing Class B holders to force the company to purchase units starting April 30, 2028.
- Purchase price for remaining units is based on a multiple of Hiya's Adjusted EBITDA.
USANA Health Sciences, Inc. filed an 8-K to announce the release of its third quarter financial results for the period ended September 28, 2024. The filing includes a press release and management commentary regarding the company's operational performance.
📋 Key Facts
- Company announced Q3 2024 financial results on October 22, 2024.
- The reporting period ended September 28, 2024.
- Management held/is holding a conference call to discuss results and provide commentary.
- Exhibits include a press release (99.1) and Management Commentary (99.2).
USANA Health Sciences, Inc. filed an 8-K to announce the release of its second quarter 2024 financial results and management commentary. The filing serves as a formal notification that earnings data is being made public via press release and an investor conference call.
📋 Key Facts
- Company announced Q2 2024 financial results on July 23, 2024.
- The reporting period ended June 29, 2024.
- Management will host a conference call to discuss results and provide a 'Management Commentary'.
- Financial information was furnished rather than filed under Section 18 of the Exchange Act.
USANA Health Sciences reported the results of its Annual Meeting of Shareholders held on May 6, 2024. The meeting included the election of eight directors and advisory votes on auditor ratification and executive compensation.
📋 Key Facts
- Annual Meeting of Shareholders held on May 6, 2024.
- Quorum reached with 17,520,055 shares (approx. 91%) represented by proxy or in person.
- Eight individuals were elected to the Board of Directors, including Kevin G. Guest and Xia Ding.
- Shareholders ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2024 with 17,458,617 votes in favor.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay) with 16,559,671 votes in favor.
USANA Health Sciences, Inc. filed an 8-K to announce its financial results for the first quarter ended March 30, 2024. The filing includes a press release and management commentary regarding the company's operational performance.
📋 Key Facts
- Report date: April 30, 2024
- Reporting period: First Quarter ended March 30, 2024
- The filing includes a press release (Exhibit 99.1) and Management Commentary (Exhibit 99.2)
- Management held/is holding a conference call to discuss results with investors
USANA Health Sciences, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 30, 2023. The filing includes a press release and management commentary regarding the company's recent operations.
📋 Key Facts
- Reported date of event: February 6, 2024.
- Financial results cover the fourth quarter and fiscal year ended December 30, 2023.
- The company issued a press release (Exhibit 99.1) and Management Commentary (Exhibit 99.2).
- Management held/scheduled a conference call to discuss results with investors.